News | May 14, 2024
Bayer Q1 2024 net income drops 8.2% to € 2 billion
EBITDA before special items falls 1.3 percent to € 4.41 billion
EBITDA before special items falls 1.3 percent to € 4.41 billion
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
The ninth acquisition since 2018
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
Subscribe To Our Newsletter & Stay Updated
